for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PDL BioPharma Inc

PDLI.OQ

Latest Trade

2.21USD

Change

0.00(0.00%)

Volume

390,857

Today's Range

2.18

 - 

2.24

52 Week Range

2.13

 - 

3.86

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.21
Open
2.23
Volume
390,857
3M AVG Volume
22.73
Today's High
2.24
Today's Low
2.18
52 Week High
3.86
52 Week Low
2.13
Shares Out (MIL)
113.98
Market Cap (MIL)
251.90
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 PDL BioPharma Inc Earnings Release

Latest Developments

More

PDL Biopharma To Complete Spin-Off Of Lensar, Inc. On October 1, 2020

Pdl Biopharma Announces Offer To Purchase Convertible Notes Due 2021 And 2024

Pdl Biopharma Announces Filing Of A Form 10 Registration Statement With The Securities And Exchange Commission For A Potential Spin-Off Of Lensar To Pdl's Stockholders

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PDL BioPharma Inc

PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be biotechs, pharmas, medtech companies, universities and inventors.

Industry

Medical Equipment & Supplies

Contact Info

932 Southwood Blvd

INCLINE VILLAGE, NV

89451

United States

+1.775.8328500

http://www.pdl.com

Executive Leadership

Elizabeth G. O'Farrell

Chairperson of the Board

Dominique Monnet

President, Chief Executive Officer, Director

Edward Imbrogno

Chief Financial Officer, Chief Accounting Officer, Vice President - Finance

Christopher Lewis Stone

Vice President, General Counsel, Secretary

John Peter McLaughlin

Director

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.2K

2019

0.1K

2020(E)

0.0K
EPS (USD)

2017

0.710

2018

-0.470

2019

-0.590

2020(E)

-0.540
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.86
Price To Book (MRQ)
0.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.21
LT Debt To Equity (MRQ)
3.21
Return on Investment (TTM)
-12.93
Return on Equity (TTM)
-12.25

Latest News

Latest News

BRIEF-Pdl Biopharma Reports 2020 First Quarter Financial Results

* QTRLY LOSS PER SHARE FROM CONTINUING OPERATIONS $0.26 Source text for Eikon: Further company coverage:

BRIEF-PDL Biopharma Plans To Dissolve Co By Year- End 2020

* QTRLY REVENUE NEGATIVE (NOT POSITIVE) $5.8 MILLION VERSUS POSITIVE REVENUE OF $45.1 MILLION

BRIEF-PDL BioPharma Names Edward A. Imbrogno As Vice President And Chief Financial Officer

* PDL BIOPHARMA ANNOUNCES APPOINTMENT OF EDWARD A. IMBROGNO AS VICE PRESIDENT AND CHIEF FINANCIAL OFFICER

BRIEF-PDL Biopharma Enters Into Cooperation Agreement With Engine Capital

* PDL BIOPHARMA ENTERS INTO COOPERATION AGREEMENT WITH ENGINE CAPITAL

BRIEF-PDL Biopharma Reports Q1 GAAP Earnings Per Share $0.01

* PDL BIOPHARMA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-PDL Biopharma Shareholder, Sevensaoi Capital, Comments On The Nomination Of Shlomo Yanai To PDL Board

* PDL BIOPHARMA SHAREHOLDER, SEVENSAOI CAPITAL, COMMENTS ON THE NOMINATION OF SHLOMO YANAI TO THE PDL BOARD OF DIRECTORS AND DELIVERS LETTER TO THE BOARD OUTLINING SIGNIFICANT CONCERNS

BRIEF-PDL Biopharma Announces Q4 Revenue Of $68 Million

* PDL BIOPHARMA ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

BRIEF-PDL Biopharma Terminates Interest In Pursuing Acquisition Of Neos

* PDL BIOPHARMA TERMINATES INTEREST IN PURSUING ACQUISITION OF NEOS

BRIEF-PDL Biopharma Inc files for non-timely 10-Q

* PDL Biopharma Inc files for non-timely 10-Q - SEC filing Source text: (http://bit.ly/2AC3Kyu) Further company coverage:

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

BRIEF-PDL Biopharma Inc reports Q3 revenue $62.7 million

* PDL Biopharma Inc announces third quarter 2017 financial results

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc <NEOS.O>, which this week rejected a fourth takeover offer by PDL Biopharma Inc <PDLI.O>, will consider offers from other potential buyers, according to people familiar with the matter.

BRIEF-PDL Biopharma issues response to Neos Therapeutics rejection of PDL acquisition proposal

* PDL Biopharma issues statement in response to Neos Therapeutics rejection of PDL acquisition proposal

BRIEF-PDL Biopharma announces settlement agreement with Valeant

* PDL Biopharma - Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement

BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma

* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash

BRIEF-PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share

* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up